Allogeneic hematopoietic cell transplantation for metastatic breast cancer

Bone Marrow Transplantation

Volumn 41, Issue 6, 2008, Pages 537-545

  Ueno, N T ^a   Rizzo, J D ^b   Demirer, T ^c   Cheng, Y C ^b   Hegenbart, U ^d   Zhang, M J ^b   Bregni, M ^e   Carella, A ^f   Blaise, D ^g   Bashey, A ^h   Bitran, J D ⁱ   Bolwell, B J ^j   Elfenbein, G J ^k   Fields, K K ^l   Freytes, C O ^m   Gale, R P ⁿ   Lazarus, H M ^o   Champlin, R E ^a   Stiff, P J ^p   Niederwieser, D ^q  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c ANKARA UNIVERSITY   (Turkey)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Institute Scientifico HS Raffaele   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g INSTITUT PAOLI CALMETTES   (France)

^h Blood and Marrow Transplant Group of Georgia   (United States)

ⁱ ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k BOSTON UNIVERSITY   (United States)

^l H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁿ Center for Advanced Studies in Leukemia   (United States)

^o UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^p LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^q UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; THIOTEPA; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NONMYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOPLASM METASTASIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 41549095493     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705940     Document Type: Article

References (37)

1. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
2. Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. Natl Cancer Inst Monogr 1986; 1: 87-94.
3. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M et al. A large prospective randomized trial of high dose combination alkylating agents (CPB) with sutologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy. (AFM). Proc Am Soc Clin Oncol 1996; 15: 121.
4. Lotz JP, Cure H, Janvier M, Morvan F, Legros M, Astelain B et al. Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: Results of the national protocol Pegase 04. Hematol Cell Ther 1999; 41: 71-74.
5. Madan B, Broadwater G, Rubin P, Edwards J, Long G, Chao NC et al. Improved survival with consolidation high dose cyclophosphamide, cisplatin and carmustine compared with observation in women with metastatic breast cancer and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate: A phase III prospective randomized comparative trial. Proc Am Soc Clin Oncol 2000; 19 48a.
6. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia bone marrow transplant group. N Engl J Med. 2000; 342: 1069-1076.
7. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem-cell transplantation (SCT) for metastatic breast cancer: 5-year update of the 'Philadelphia trial' (PBT-1). Proc Am Soc Clin Oncol 2002; 21: 43a.
8. Cruamp, M, Gluck S, Stewart.D, Levine M, Pritchard K, Kirkbride P et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: A National cancer institute of Canada (NCIC) clinical trials group study. Proc Am Soc Clin Oncol 2001; 20: 21a.
9. Biron P, Durand M, Roche H, Delozier T, Battista C, Fargeot P et al High dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first fine chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole. Proc Am Soc Clin Oncol 2002; 21: 42a.
10. Crown JP, Leyvraz S, Verrill M, Guillem, Efremidis A, Garcia-Conde Bru J et al. Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I. Proc Am Soc Clin Oncol 2004; 23: 35s.
11. Schmid P, Schippinger W, Nitsch T, Huebner G, Kreienberg R, Schultze W et al. Up front tandem high-dose chemotherapy (HD) compared to standard chemotherapy with doxorubicin and paclitaxel (AT) in metastatic breast cancer (MBC): Final results of a randomized trial. Proc Am Soc Clin Oncol 2004; 23: 37s.
12. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
13. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
14. Porter DL, Roth MS, Lee SJ, McGarigle C, Ferrara JL, Antin JH. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 975-980.
15. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
16. Khouri IF, Keating M, Korbling M, Przepiorka,.D, Anderlini P, O'Brien S et al. Transplant-lite: Induction of graft-versus-malignancy using fludaribine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
17. Khouri IF, Lee MS, Romaguera J, Mirza N, Kantadian H, Korbling M et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293-1299.
18. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol 1984; 132: 997-1000.
19. Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R et al Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
20. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus, leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996; 348: 1242-1243.
21. Oblon DJ, Paul S, Yankee R. Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE). Bone Marrow Transplant 1997; 20: 421-423.
22. Or R, Ackerstein A, Nagler A, Kapelushnik J, Naparstek E, Samuel S et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical- pilot study. Cytokines Cell Mol Ther 1999, 4: 1-6.
23. Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA et al Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986-993.
24. Bregni M, Dodero-A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234-4236.
25. Carella AM, Beltrami G, Lerma E, Cavaliere M, Corsetti MT. Combined use of autografting and non-myeloahlative allografting for the treatment of hematologic malignancies and metastatic breast cancer. Cancer Treat Res 2002; 110: 10 1-112.
26. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen conigiped of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829-3836.
27. Blaise D, Bay JO, Faucher C, Michallet M, Boiron JM, Choufi B et al Reduced-intensity preparative regimnen and allogeneic stem cell transplantation for advanced solid tumors. Blood 2004; 103: 435-441.
28. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg SM et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
29. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-320.
30. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191-195.
31. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization Offset Publication No. 48: Geneva (Switzerland), 1979.
32. Gooley TA, Leisenring W, Crowle J, Storer BE. Estimation of failure probabilities in the y presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
33. Morecki S, Yacovlev E, Gelfand Y, Uzi I, Slavin S. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother 2001; 24: 114-121.
34. Panigrahi S, Yacovlev E, Gelfand Y, Schuger U, Slavin S, Morecki S. Intraportal and systemic allogeneic cell therapy in a murine model of hepatic metastatic breast cancer. Cytokines Cell Mol Ther 2002; 7: 99-106.
35. Morecki S, Yacovlev E, Gelfand Y, Vilensky A, Slavin S. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect. Biol Blood Marrow Transplant 2004; 10: 40-48.
36. Fuzak J, Jung U, Foley J, Eckhaus MA, Fowler DH, Bishop MR. Allospecific Tc2 cells mediate a graft-versus-tumor effect without inducing ongoing GVHD in a murine model of metastatic breast cancer. Blood 2000; 96: 551a.
37. Prigozhina TB, Gurevitch O, Morecki S, Yakovlev E, Elkin G, Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol 2002; 30: 89-96.